Description of Business, Basis of Presentation and Significant Accounting Policies (Tables)
|6 Months Ended|
May 31, 2021
|Accounting Policies [Abstract]|
|Schedule of Assets and Liabilities From Contracts With Customers||
The following table provides information about assets and liabilities from contracts with customers:
The Company, in general, requires the customer to pay for processing and storage services at the time of processing. Contract assets include deferred contract acquisition costs, which will be amortized along with the associated revenue. Contract liabilities include payments received in advance of performance under the contract and are realized with the associated revenue recognized under the contract. Accounts receivable consists of amounts due from clients that have enrolled and processed in the umbilical cord blood stem cell processing and storage programs related to renewals of annual plans and amounts due from license affiliates, and sublicensee territories. The Company did not have asset impairment charges related to contract assets in the three and six months ended May 31, 2021 and May 31, 2020.
The following table presents changes in the Company’s contract assets and liabilities during the six months ended May 31, 2021:
The following table presents changes in the Company’s contract assets and liabilities during the six months ended May 31, 2020:
|Financial Assets and Liabilities Measured at Fair Value on Recurring Basis||
The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of May 31, 2021 and November 30, 2020, respectively, segregated among the appropriate levels within the fair value hierarchy:
No definition available.
Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
Reference 1: http://www.xbrl.org/2003/role/disclosureRef